AstraZeneca appoints new global head of product PR
pharmafile | July 15, 2004 | News story | |
AstraZeneca has appointed a new head of global public relations to oversee strategic public relations programmes and all other aspects of PR activities around the world.
Margaret Morgan joins the company as global director of PR from September, taking over from Cathy Kernen who has returned to the company's US operations to take on the role of senior director of allied development.
Ms Morgan has considerable experience and joins the company from UCB Pharma in Brussels were she was head of communications for the company's pharma operations.
Prior to UCB she worked as vice president communications at Merial, the Merck/Aventis animal health joint venture, establishing lobbying and public affairs as part of her role there. She also has extensive experience of product communications across key therapy areas from positions at MSD in the UK and globally with GlaxoWellcome.
Carlos Felippe, vice president strategic medical and marketing communications AstraZeneca, said: "Margaret has a wealth of experience across corporate and product communications at a global level, and I am delighted to have her on board. She joins AstraZeneca at an exciting time for the company as we continue to drive public relations programmes that increase the profile of AstraZeneca and our products across our audiences."
"I am very excited to be joining AstraZeneca in this important role," added Ms Morgan. "I look forward to working with what I know are a great team, and relish the challenge of leading ground-breaking global programmes across the company's therapy areas."
One of the biggest challenges facing the global product PR team Ms Morgan will inherit, is the global roll-out of the company's latest 'megabrand' candidate Exanta, the first new oral anticoagulant in sixty years and the first in a new class of drugs called direct thrombin inhibitors.
Related articles:
Exanta launched in first market
Wednesday, June 23, 2004
